Interact Reference Component

The discovery of genetic biomarkers and their subsequent application in oncology research are paving the path toward a future in targeted therapy development, linking genes to disease states and prognosis and, ultimately, more effective treatments. Learn about how our targeted next-generation sequencing panel and workflow, as well as our curated bioinformatics database and services, help deliver powerful solutions for drug and companion diagnostic development.

Featured products


Preclinical to companion diagnostic solutions

Targeted sequencing assays for oncology research. Include content for DNA and RNA, FFPE and liquid biopsy samples.

A more informative approach to assay design and reporting based on our collective understanding of published cancer research and data.

Using NGS data to help inform therapy selection

Dr. Giselle Sholler

Pediatric cancers are challenging because their origins differ from adult cancers, and because historically many of the tools used to study adult cancers have not been adapted for pediatric studies.

That is changing. Pediatric oncologists are not only working with NGS data, they are seeking it out, helping drive the future of pediatric cancer care.

Watch the video ?

Comparison of Oncomine assay and Ion AmpliSeq panel content

Targeted next-generation sequencing (NGS) is empowering laboratories of all sizes to confidently pioneer breakthroughs in cancer research. At the core of these breakthroughs are assays and panels designed to achieve highly sensitive results from minimal sample input—to help deliver information that may lead to the next companion diagnostic test or therapy in the future.

Clinical cancer research requires countless decisions. Of critical importance are the decisions you make about assay content. This comparison of the Ion Oncomine assay and Ion AmpliSeq panel content is designed to help you tailor your content choices.

Examples of Oncomine assays and Ion AmpliSeq panels and a subset of their associated genes and tumor types for research use. The Oncomine Knowledgebase shows that the specific gene had a variant detected in specific tumor type at a minimum of a 1% frequency. Additional genes are available on these and other Oncomine assays and Ion AmpliSeq panels.
 Click to enlarge

Assays designed with industry leaders, informed by big data

More and more, researchers recognize the importance of an integrated approach to more effectively advancing oncology research. Our targeted next-generation sequencing (NGS) solutions are designed using information in the Oncomine Knowledgebase and confirmed with industry-leading partners to deliver powerful solutions for drug and companion diagnostic development.

Figure 1. The Oncomine Knowledgebase.

Figure 2. Content and informatics solutions informed by the Oncomine Knowledgebase result in assays that help accelerate your research to move from preclinical toward the future of companion diagnostics.